China's Taibang Biologic raises US$300m, led by ADIA unit, GIC
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
CHINA’S Taibang Biologic Group raised US$300 million to finance growth in a fundraising led by sovereign wealth funds Abu Dhabi Investment Authority (ADIA) and Singapore’s GIC, the biopharmaceutical firm said on Tuesday (Aug 2).
Apart from Platinum Orchid, a subsidiary of the United Arab Emirates’ biggest sovereign wealth fund ADIA, and GIC, new investors included state-owned China Life’s private equity arm - China Life Private Equity Investment - and Cinda Kunpeng (Shenzhen) Investment Management Co, Taibang said in a statement.
Taibang makes and sells plasma products and was previously known as China Biologic Products Holdings, as per the statement.
The proceeds will be used to finance its expansion of plasma stations and its research and development of new products, the statement said.
The deal marks Taibang’s first equity financing transaction since the completion of its privatisation in April last year by a consortium led by Chinese private equity firm Centurium Capital. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
